Transcriptomics

Dataset Information

114

Validation cohort for genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer


ABSTRACT: PURPOSE: To develop a predictive test for response and survival following neoadjuvant taxane-anthracycline chemotherapy for HER2-negative invasive breast cancer. METHODS: We developed a microarray-based gene expression test from pre-treatment tumor biopsies (310 patients) to predict favorable outcome based on estrogen receptor (ER) status,pathologic response to chemotherapy, 3-year disease outcomes, and sensitivity to endocrine therapy. Tumors were classified as treatment-sensitive if predicted to have pathologic response (and not resistance) to chemotherapy, or sensitive to endocrine therapy. We tested predictive accuracy, with 95% confidence interval (CI), for pathologic response (PPV, positive predictive value), distant relapse-free survival (DRFS), and absolute risk reduction at median follow-up in 198 other patients. Independence from clinical-pathologic factors was assessed in a multivariate Cox regression analysis based on the likelihood ratio test. Other evaluable, published response predictors (genomic grade index (GGI), intrinsic subtype (PAM50), pCR predictor (DLDA30)) were compared. Neoadjuvant validation cohort of 198 HER2-negative breast cancer cases treated with taxane-anthracycline chemotherapy pre-operatively and endocrine therapy if ER-positive. Response was assessed at the end of neoadjuvant treatment and distant-relapse-free survival was followed for at least 3 years post-surgery.

ORGANISM(S): Homo sapiens  

SUBMITTER: Tatiana Vidaurre   Frankie Holmes  W F Symmans  Miguel Martin  Christos Hatzis  Eduardo Souchon 

PROVIDER: E-GEOD-25065 | ArrayExpress | 2011-05-11

SECONDARY ACCESSION(S): GSE25065PRJNA142731

REPOSITORIES: GEO, ArrayExpress

altmetric image

Publications


CONTEXT:Prediction of high probability of survival from standard cancer treatments is fundamental for individualized cancer treatment strategies. OBJECTIVE:To develop a predictor of response and survival from chemotherapy for newly diagnosed invasive breast cancer. DESIGN, SETTING, AND PATIENTS:Prospective multicenter study conducted from June 2000 to March 2010 at the M. D. Anderson Cancer Center to develop and test genomic predictors for neoadjuvant chemotherapy. Patients were those with newly  ...[more]

Similar Datasets

2011-05-11 | E-GEOD-25055 | ArrayExpress
2011-05-11 | E-GEOD-25066 | ArrayExpress
| GSE87455 | GEO
2020-01-01 | E-MTAB-7634 | ArrayExpress
2017-06-30 | E-MTAB-4439 | ArrayExpress
2015-01-21 | E-GEOD-48073 | ArrayExpress
2015-06-12 | E-GEOD-32603 | ArrayExpress
2019-01-02 | PXD010292 | Pride
| PRJNA134729 | ENA
2014-08-31 | E-GEOD-56259 | ArrayExpress